USPTO 2015–2025 USPTO PatentsView US Corporation

PTC Therapeutics, Inc.

USPTO PatentsView assignee record - 111 granted patents across 20 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

111

Total patents granted

CPC technology areas

14.5

Avg claims per patent

+9%

5-year filing velocity

The verdict

PTC holds 111 US patents across 20 technology areas, rank #3,355 of 50,000 tracked assignees.

#3,355
of 50,000 US assignees by volume: Top 22%
by Innovation Score (46.0/100): 14.5
avg claims per patent: +9%
filing velocity, last 5 yrs

Portfolio overview

PTC Therapeutics, Inc. has been granted 111 US utility patents between 2015 and 2025, placing PTC Therapeutics, Inc. at rank #3,355 across all assignees tracked by PlainPatent. This portfolio spans 20 distinct Cooperative Patent Classification (CPC) subclasses, averaging 14.5 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, PTC Therapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, PTC sits between Macneil IP Llc (111 patents, rank #3,351) and SCA IPLA Holdings Inc. (111 patents, rank #3,359) - the closest US assignees by grant volume. The composite Innovation Score of 46.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 58 grants, compared with 53 in the 2015–2019 window, a +9% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. PTC Therapeutics, Inc.'s 14.5 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 20 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark PTC Therapeutics, Inc. against peers pursuing similar technology classes.

Macneil IP

111
MUSC Foundation f…

111
Millerknoll

111
Neuropace

111
ROM

111
S V V Technology…

111
Sagemcom Energy &…

111
SCA IPLA Holdings

111
PTC Therapeutics ◀

111

What this shows PTC holds 111 patents at rank #3,355, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near PTC

By rank, the assignees closest to #3,355 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in PTC's primary technology class.

PTC's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

46 Top 22% higher than 78% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

PTC Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	11	9.9%
2016	16	14.4%
2017	6	5.4%
2018	10	9.0%
2019	10	9.0%
2020	14	12.6%
2021	12	10.8%
2022	8	7.2%
2023	15	13.5%
2024	5	4.5%
2025	4	3.6%

Which technologies does PTC Therapeutics, Inc. patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 90

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 72

C07D - HETEROCYCLIC COMPOUNDS 72

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 15

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 11

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 10

C07B - GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR 8

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 8

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 8

C07F - ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM 6

C07K - PEPTIDES 3

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY 2

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 1

C12Y - ENZYMES 1

A01N - PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF ; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES ; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS 1

Top 15 of 20 technology areas

Patent Moat Analysis

Portfolio Volume Moderate

Tech Breadth Multi-domain

Claim Depth Standard

Velocity Growing

Where it ranks

Overall rank by patents

#3,355

Across all tracked assignees

Innovation Score

46.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does PTC Therapeutics, Inc. hold?

PTC Therapeutics, Inc. holds 111 US granted patents filed between 2015 and 2025, spanning 20 technology areas.

What is PTC Therapeutics, Inc.'s Innovation Score?

PTC Therapeutics, Inc. has an Innovation Score of 46.0 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does PTC Therapeutics, Inc. focus on?

PTC Therapeutics, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 90 patents. The company has filed patents in 20 CPC subclasses total.

Is PTC Therapeutics, Inc.'s patent filing rate increasing or decreasing?

PTC Therapeutics, Inc.'s recent filing velocity is +9% compared to the prior five-year period. The company is maintaining or growing its patent output.

What does claim depth mean for PTC Therapeutics, Inc.'s patents?

PTC Therapeutics, Inc.'s patents average 14.5 claims each. This falls within the standard range, providing solid legal coverage.

How is the PTC Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

PTC's 111 grants land it in the top 22% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - PTC ranks #3,355 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.